ABSORB EXTEND: an Interim 12-month propensity adjusted comparison of clinical outcomes of approximately 450 ABSORB patients to XIENCE V patients

Abstract

Purpose: The Absorb Bioresorbable Vascular Scaffold (BVS) has been designed based upon the MULTI-LINK VISION family of stents which includes the XIENCE V EES. Both designs have shown consistency in acute radial strength and recoil. Everolimus is the drug of choice for the Absorb BVS and the XIENCE V EES and both contain 100ug/cm2 of the drug with identical elution profiles. Therefore, similarities between these two devices allow for relevant comparison of the results obtained in the SPIRIT II and SPIRIT III studies using the XIENCE V and the ABSORB EXTEND study using the Absorb BVS. Methods: Approximately 450 patients enrolled in ABSORB EXTEND will be compared to patients from the SPIRIT II and SPIRIT III studies using propensity score adjustment in an effort to provide comparative data on the safety and performance of the Absorb BVS System in a larger population of patients, including those with longer lesions and dual vessel treatment when compared to XIENCE V. Results: A propensity adjusted descriptive comparison of clinical and lesion characteristics, and procedural and clinical outcomes between the two populations will be presented through 12 months. View this table: Unadjusted baseline characteristics Conclusion: Interim outcomes in approximately 450 patients through 12 months from ABSORB EXTEND (the largest patient cohort reported at this time point to date) and a propensity adjusted comparison to XIENCE V will provide further insight into the longer-term safety and efficacy of the Absorb BVS System.